

Ferrer, Barcelona, Spain

- (1) Abian J, Steg PG, Stone GW, Manolis AG, Angiolillo KW, Gibson CM, Hamm CW, et al. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. *JACC Cardiovasc Interv.* 2016 Sep 26;9(18):1905-13.
- (2) Capodanno D, Ferrero JL, Angiolillo DJ. Antiplatlet therapy: new pharmacological agents and changing paradigms. *J Thromb Haemost.* 2013 Jun;11 (Suppl 1):316-29.
- (3) Nairouz R, Feldman DN, Rochlani Y, Aronow WS, Sardar P, Mukherjee D, et al. Impact of intraprocedural thrombotic events on short- and long-term outcomes following percutaneous coronary intervention. Evidence from a meta-analysis. *Int J Cardiol.* 2016 Jan 1;202:469-76.
- (4) Tamez H, Générucq P, Yeh RW, Amin AP, Fan W, White HD, et al. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. *Catheter Cardiovasc Interv.* 2018 May 4.
- (5) Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Jucci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J.* 2018;39(2):119-77.
- (6) Park CB, Hwang HJ, Cho JM, Jo BH, Kim CJ. Acute myocardial infarction patient with recurrent vomiting: What is the best treatment? *Int J Cardiol.* 2013 Jan 20;162(3):e56-7.
- (7) European Medicines Agency (EMA). Summary of product characteristics: Kengrexal 50 mg powder for concentrate for solution for injection / infusion. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003773/WC500188098.pdf (accessed: 29/10/2019).